This report aims to provide a comprehensive presentation of the global market for Circulating Tumor DNA Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor DNA Diagnostics. This report contains market size and forecasts of Circulating Tumor DNA Diagnostics in global, including the following market information:
Global Circulating Tumor DNA Diagnostics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Circulating Tumor DNA Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Test Kits Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Circulating Tumor DNA Diagnostics include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc. and CellMax Life, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Circulating Tumor DNA Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor DNA Diagnostics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Circulating Tumor DNA Diagnostics Market Segment Percentages, by Type, 2022 (%)
Test Kits
Reagents
Global Circulating Tumor DNA Diagnostics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Circulating Tumor DNA Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes
Global Circulating Tumor DNA Diagnostics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Circulating Tumor DNA Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Circulating Tumor DNA Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Circulating Tumor DNA Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life
Outline of Major Chapters:
Chapter 1: Introduces the definition of Circulating Tumor DNA Diagnostics, market overview.
Chapter 2: Global Circulating Tumor DNA Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Circulating Tumor DNA Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Circulating Tumor DNA Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Circulating Tumor DNA Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Circulating Tumor DNA Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Circulating Tumor DNA Diagnostics Overall Market Size
2.1 Global Circulating Tumor DNA Diagnostics Market Size: 2022 VS 2030
2.2 Global Circulating Tumor DNA Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Circulating Tumor DNA Diagnostics Players in Global Market
3.2 Top Global Circulating Tumor DNA Diagnostics Companies Ranked by Revenue
3.3 Global Circulating Tumor DNA Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Circulating Tumor DNA Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Circulating Tumor DNA Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Tumor DNA Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Circulating Tumor DNA Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Circulating Tumor DNA Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Circulating Tumor DNA Diagnostics Market Size Markets, 2022 & 2030
4.1.2 Test Kits
4.1.3 Reagents
4.2 By Type - Global Circulating Tumor DNA Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Circulating Tumor DNA Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Circulating Tumor DNA Diagnostics Revenue, 2024-2030
4.2.3 By Type - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Circulating Tumor DNA Diagnostics Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Diagnostics Laboratories
5.1.4 Research Laboratories
5.1.5 Academic Research Institutes
5.2 By Application - Global Circulating Tumor DNA Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Circulating Tumor DNA Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Circulating Tumor DNA Diagnostics Revenue, 2024-2030
5.2.3 By Application - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Circulating Tumor DNA Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Circulating Tumor DNA Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Circulating Tumor DNA Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Circulating Tumor DNA Diagnostics Revenue, 2024-2030
6.2.3 By Region - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.3.2 US Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.3.3 Canada Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.3.4 Mexico Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.4.2 Germany Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.3 France Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.4 U.K. Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.5 Italy Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.6 Russia Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.4.8 Benelux Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.5.2 China Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.3 Japan Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.4 South Korea Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.5.6 India Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.6.2 Brazil Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.6.3 Argentina Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Circulating Tumor DNA Diagnostics Revenue, 2018-2030
6.7.2 Turkey Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7.3 Israel Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Circulating Tumor DNA Diagnostics Market Size, 2018-2030
6.7.5 UAE Circulating Tumor DNA Diagnostics Market Size, 2018-2030
7 Circulating Tumor DNA Diagnostics Companies Profiles
7.1 Grail, Inc.
7.1.1 Grail, Inc. Company Summary
7.1.2 Grail, Inc. Business Overview
7.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Grail, Inc. Key News & Latest Developments
7.2 Guardant Health, Inc.
7.2.1 Guardant Health, Inc. Company Summary
7.2.2 Guardant Health, Inc. Business Overview
7.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Guardant Health, Inc. Key News & Latest Developments
7.3 Biodesix, Inc.
7.3.1 Biodesix, Inc. Company Summary
7.3.2 Biodesix, Inc. Business Overview
7.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Biodesix, Inc. Key News & Latest Developments
7.4 Exosome Diagnostics
7.4.1 Exosome Diagnostics Company Summary
7.4.2 Exosome Diagnostics Business Overview
7.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Major Product Offerings
7.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Exosome Diagnostics Key News & Latest Developments
7.5 Freenome Inc.
7.5.1 Freenome Inc. Company Summary
7.5.2 Freenome Inc. Business Overview
7.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Freenome Inc. Key News & Latest Developments
7.6 LungLife AI, Inc.
7.6.1 LungLife AI, Inc. Company Summary
7.6.2 LungLife AI, Inc. Business Overview
7.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.6.5 LungLife AI, Inc. Key News & Latest Developments
7.7 Inivata Ltd.
7.7.1 Inivata Ltd. Company Summary
7.7.2 Inivata Ltd. Business Overview
7.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Major Product Offerings
7.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Inivata Ltd. Key News & Latest Developments
7.8 Personal Genome Diagnostics, Inc.
7.8.1 Personal Genome Diagnostics, Inc. Company Summary
7.8.2 Personal Genome Diagnostics, Inc. Business Overview
7.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Major Product Offerings
7.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Personal Genome Diagnostics, Inc. Key News & Latest Developments
7.9 CellMax Life
7.9.1 CellMax Life Company Summary
7.9.2 CellMax Life Business Overview
7.9.3 CellMax Life Circulating Tumor DNA Diagnostics Major Product Offerings
7.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue in Global Market (2018-2023)
7.9.5 CellMax Life Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Circulating Tumor DNA Diagnostics Market Opportunities & Trends in Global Market
Table 2. Circulating Tumor DNA Diagnostics Market Drivers in Global Market
Table 3. Circulating Tumor DNA Diagnostics Market Restraints in Global Market
Table 4. Key Players of Circulating Tumor DNA Diagnostics in Global Market
Table 5. Top Circulating Tumor DNA Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Circulating Tumor DNA Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Circulating Tumor DNA Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Circulating Tumor DNA Diagnostics Product Type
Table 9. List of Global Tier 1 Circulating Tumor DNA Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Circulating Tumor DNA Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Circulating Tumor DNA Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Circulating Tumor DNA Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Circulating Tumor DNA Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Circulating Tumor DNA Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Circulating Tumor DNA Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Circulating Tumor DNA Diagnostics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2024-2030
Table 30. Grail, Inc. Company Summary
Table 31. Grail, Inc. Circulating Tumor DNA Diagnostics Product Offerings
Table 32. Grail, Inc. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Grail, Inc. Key News & Latest Developments
Table 34. Guardant Health, Inc. Company Summary
Table 35. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product Offerings
Table 36. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Guardant Health, Inc. Key News & Latest Developments
Table 38. Biodesix, Inc. Company Summary
Table 39. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product Offerings
Table 40. Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Biodesix, Inc. Key News & Latest Developments
Table 42. Exosome Diagnostics Company Summary
Table 43. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product Offerings
Table 44. Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Exosome Diagnostics Key News & Latest Developments
Table 46. Freenome Inc. Company Summary
Table 47. Freenome Inc. Circulating Tumor DNA Diagnostics Product Offerings
Table 48. Freenome Inc. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Freenome Inc. Key News & Latest Developments
Table 50. LungLife AI, Inc. Company Summary
Table 51. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product Offerings
Table 52. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. LungLife AI, Inc. Key News & Latest Developments
Table 54. Inivata Ltd. Company Summary
Table 55. Inivata Ltd. Circulating Tumor DNA Diagnostics Product Offerings
Table 56. Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Inivata Ltd. Key News & Latest Developments
Table 58. Personal Genome Diagnostics, Inc. Company Summary
Table 59. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product Offerings
Table 60. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Personal Genome Diagnostics, Inc. Key News & Latest Developments
Table 62. CellMax Life Company Summary
Table 63. CellMax Life Circulating Tumor DNA Diagnostics Product Offerings
Table 64. CellMax Life Circulating Tumor DNA Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. CellMax Life Key News & Latest Developments
List of Figures
Figure 1. Circulating Tumor DNA Diagnostics Segment by Type in 2022
Figure 2. Circulating Tumor DNA Diagnostics Segment by Application in 2022
Figure 3. Global Circulating Tumor DNA Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Circulating Tumor DNA Diagnostics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Circulating Tumor DNA Diagnostics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Circulating Tumor DNA Diagnostics Revenue in 2022
Figure 8. By Type - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 16. US Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 20. Germany Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 21. France Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 28. China Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 32. India Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 34. Brazil Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Circulating Tumor DNA Diagnostics Revenue Market Share, 2018-2030
Figure 37. Turkey Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Circulating Tumor DNA Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 41. Grail, Inc. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Freenome Inc. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. CellMax Life Circulating Tumor DNA Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
